From clinical trial site to one of the few institutions in the country authorized to deliver all available FDA-approved CAR T-cell therapies, Fox Chase Cancer Center describes its successful evolution and identifies effective practices to help community cancer centers surmount the financial barriers to therapy as well as build strong referral networks with institutions offering cellular therapies.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
